Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis.
about
Emerging drugs for uveitisNew Immunosuppressive Therapies in Uveitis TreatmentAnti-TNF therapy for juvenile idiopathic arthritis-related uveitisWhat does an adult rheumatologist need to know about juvenile idiopathic arthritis?The Future Is Now: Biologics for Non-Infectious Pediatric Anterior UveitisProfile of adalimumab and its potential in the treatment of uveitisIntravenous laser blood irradiation increases efficacy of etanercept in selected subtypes of juvenile idiopathic arthritis: an innovative clinical research approach.Efficacy of adalimumab in young children with juvenile idiopathic arthritis and chronic uveitis: a case seriesPharmacotherapy for uveitis: current management and emerging therapy.Response of pediatric uveitis to tumor necrosis factor-α inhibitors.The development and assessment of biological treatments for children.Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs.Current perspectives on ophthalmic manifestations of childhood rheumatic diseasesFactors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers.Adalimumab for Ocular Inflammation.Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature.Pharmacotherapy of scleritis: current paradigms and future directions.A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial).Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis.Role of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions.Update on the use of systemic biologic agents in the treatment of noninfectious uveitis.Biologics in children's autoimmune disorders: efficacy and safety.Adalimumab (humira™) in ophthalmology: a review of the literature.Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology.Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis.The role of biologic agents in the management of non-infectious uveitis.Susceptibility genes and pharmacogenetics in ocular inflammatory disorders.Systemic treatment of vitreous inflammation.Update on biologicals for treatment of juvenile idiopathic arthritis.Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis.TNF inhibition for ophthalmic indications: current status and outlook.Systemic treatments for noninfectious vitreous inflammation.Adalimumab in the treatment of immune-mediated diseases.Treatment of uveitis associated with juvenile idiopathic arthritis.Judicious use of biologicals in juvenile idiopathic arthritis.The Use of Biologic Therapies in Uveitis.Treatment Options for Juvenile Idiopathic Arthritis (JIA) Associated Uveitis.Recent advances in the use of Anti-TNFα therapy for the treatment of juvenile idiopathic arthritis.Progress in the understanding and utilization of biologic response modifiers in the treatment of uveitis.Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis.
P2860
Q24630848-F7C998AA-1AD1-40A8-81BC-A2AA44A3A575Q26798201-E1DCAD3E-07F1-4431-A447-A84432F67942Q26849811-BE050E8D-E6CD-4E1D-8CD9-BB453CACFABAQ26995394-BBACC3DF-B54F-4FD2-8C18-C8F6EBB3F69FQ27025862-67458800-68B7-4475-9F27-E71394050347Q28077781-A0E7C047-DE49-4B8D-83E2-195BBFB8D688Q31130038-9773A47E-1659-4912-A86D-875AD82F2D34Q33712570-6E1B7C6C-AA4B-4D74-A67B-BD30E62A5A05Q34274075-FEEBF1DA-1F60-445E-810B-8C398601284AQ34789195-D43C007A-6135-4D57-B9F2-0F71184ADCD3Q35135936-FC9B0226-52CE-431C-A348-4BF09D5346C7Q35150941-838D92C9-C5C3-48F5-AB82-732143708C6BQ37007652-8DC90912-3960-4C1A-ABA7-2CB27FBFE32FQ37195338-0EE90D12-C604-4B21-931F-B9A051E76ECFQ37276953-F0A75466-3930-4B50-8A4B-3D32952CE00EQ37463702-29AF819B-661E-468B-9079-F00EAFF2698FQ37466204-BA45FE70-C5D4-4785-9027-6D40E6569FE6Q37479820-5E3B105F-65D7-476B-928F-1A5BE92FC988Q37482393-33F5CFAA-5153-459A-8831-D2FF90BBFC70Q37561994-BB3872D5-69E2-44FB-9131-6F3A8DE461DCQ37600483-F82C85EF-F7C4-4162-9D4A-12AEDDEF6417Q37765830-6958D23B-15C0-4298-9F26-4078953246C5Q37823308-E413B286-F9FB-49B5-9307-808D4E211C7DQ37834466-74AF03C0-A999-4A43-97C6-A596BF67A087Q37956187-262D92FA-C75B-4B12-BC13-07B24735C767Q38025152-D75919E6-3B86-4A3D-905E-F7C981B9C9CFQ38043013-BB1A159C-0B52-4C56-93E3-B0D4A6333541Q38048774-AFFCE9C8-56A7-4943-85B5-374A6E032373Q38071693-631BCAA2-8765-4BE4-AE8F-22350F0D9280Q38074446-3AE896A4-229D-4865-9028-22803A84CAB9Q38097327-5C3768A4-2806-444A-BBBC-039FFD8A0307Q38172090-79347C24-6819-450D-BF6D-15F543A563F8Q38207760-062F33EB-C562-4CEB-8394-D4B031062704Q38221012-A5092DF5-3B0B-42EF-A34D-CB87DBAF98C1Q38248905-DF1830E7-D6E3-401E-AC19-B7AD9D5315E4Q38272248-364E8AF9-3226-4836-8549-819BF20C4B47Q38664517-93970A7C-A07D-42BF-A9A3-0A24DDF33DBBQ38711172-85288A78-B434-4344-864D-E87F505B2FBBQ38773144-175154F6-B152-4AD4-9FA6-D0FC8FC101F0Q38779665-682893B6-4C25-47E7-89D3-0A07D5F2704B
P2860
Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis.
@en
Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis.
@nl
type
label
Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis.
@en
Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis.
@nl
prefLabel
Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis.
@en
Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis.
@nl
P2093
P921
P356
P1433
P1476
Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis.
@en
P2093
K Kotaniemi
P Lahdenne
V Honkanen
P304
P356
10.1093/RHEUMATOLOGY/KEM356
P577
2008-01-31T00:00:00Z